Combination therapy with lopinavir/ritonavir, ribavirin and interferon-a for Middle East respiratory syndrome

Antiviral Therapy

Volumn 21, Issue 5, 2016, Pages 455-459

  Kim, Uh Jin ^a   Won, Eun Jeong ^a   Kee, Seung Jung ^a   Jung, Sook In ^a   Jang, Hee Chang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; BILIRUBIN; C REACTIVE PROTEIN; HEMOGLOBIN; LOPINAVIR PLUS RITONAVIR; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; RIBAVIRIN; ANTIVIRUS AGENT; LOPINAVIR; RITONAVIR;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; CONVALESCENCE; CORONAVIRUS INFECTION; COUGHING; DISEASE DURATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; KOREAN (PEOPLE); LABORATORY TEST; LEUKOCYTE COUNT; LOADING DRUG DOSE; LUNG INFILTRATE; MALE; MEDICAL HISTORY; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NOSE SMEAR; PARATHYROID HORMONE BLOOD LEVEL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPEAT PROCEDURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; THROAT CULTURE; THROMBOCYTE COUNT; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS PNEUMONIA; WEAKNESS; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; SOUTH KOREA; VIROLOGY;

ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON-ALPHA; LOPINAVIR; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; REPUBLIC OF KOREA; RIBAVIRIN; RITONAVIR;

EID: 84991434329     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3002     Document Type: Article

References (16)

1. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386:995-1007.
2. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19:1313-1317.
3. Falzarano D, de Wit E, Martellaro C, et al. Inhibition of novel b coronavirus replication by a combination of interferon-a2b and ribavirin. Sci Rep 2013; 3:1686.
4. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014; 14:1090-1095.
5. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015; 70:2129-2132.
6. Al-Tawiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20:42-46.
7. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ ritonavir in the treatment of SARS: initial virological and clinical indings. Thorax 2004; 59:252-256.
8. De Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identiies four smallmolecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58:4875-4884.
9. Spanakis N, Tsiodras S, Haagmans BL, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014; 44:528-532.
10. Memish ZA, Al-Tawiq JA, Makhdoom HQ, et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 2014; 210:1590-1594.
11. Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013; 381:2265-2272.
12. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606-616.
13. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211:80-90.
14. Corti D, Zhao J, Pedotti M, et al. Prophylactic and postexposure eficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A 2015; 112:10473-10478.
15. World Health Organization. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected. (Updated 2 July 2015. Accessed 30 August 2015.) Available from http://apps.who.int/iris/bitstream/10665/178529/1/ WHO-MERS-Clinical-15.1-eng.pdf?ua=1
16. Momattin H, Mohammed K, Zumla A, et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013; 17:e792-e798.